STOCK TITAN

UNITY Biotechnology to Participate in Upcoming March Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will participate in the following upcoming March virtual investor conferences:

Cowen 41st Annual Healthcare Conference
Date: March 3, 2021
Presentation Time: 1:20 p.m. ET

33rd Annual ROTH Conference
Date: March 15, 2021
Presentation Time: 4:00 p.m. ET

A live audio webcast of the presentations will be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following each event.

About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.


Unity Biotechnology Inc

NASDAQ:UBX

UBX Rankings

UBX Latest News

UBX Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Health Technology, Biotechnology
US
Brisbane

About UBX

unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.